ABBV vs DDOG: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Datadog, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-11.
AbbVie Inc. · Healthcare
$208.05
+4.5% upside to fair value
Grade C
High Quality
VS
Datadog, Inc. · Technology
$104.77
+55.6% upside to fair value
Grade B
High Quality
QuantHub Verdict
DDOG has more upside to fair value
(+55.6%).
ABBV trades at a lower forward P/E
(14.9x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
DDOG |
| Current Price |
$208.05 |
$104.77 |
| Fair Value Estimate |
$217.50 |
$163.01 |
| Upside to Fair Value |
+4.5%
|
+55.6%
|
| Market Cap |
$367.9B |
$37.1B |
| Forward P/E |
14.9x
|
341.2x
|
| EV / EBITDA |
16.7x
|
168.3x
|
| Price / Sales |
6.1x
|
10.8x
|
| Price / FCF |
20.9x
|
37.0x
|
| Revenue Growth YoY |
+8.6%
|
+7.6%
|
| Gross Margin |
83.7%
|
79.9%
|
| Operating Margin |
34.7%
|
-1.3%
|
| Return on Equity |
-129.24%
|
3.2%
|
| Dividend Yield |
3.2% |
0% |
| FCF Yield |
4.78%
|
2.7%
|
| Analyst Consensus |
Buy
|
Strong Buy
|
Investment Thesis
AbbVie is a leading diversified biopharmaceutical company navigating the post-Humira transition with strong momentum from Skyrizi and Rinvoq in immunology and continued growth in neuroscience. Full-year 2025 revenue reached $61.2 billion with a gross margin of 83.7% and operating margin of 34.7%, demonstrating operational strength despite the ongoing Humira erosion. Management guides to $67 billi…
Datadog, Inc. is a leading cloud-based monitoring and analytics platform specializing in observability and security for cloud-native, microservices, and AI applications. The company benefits from strong product-market fit driven by extensive integrations and a customer-centric approach, reflected in 26% revenue growth to $3.43 billion in fiscal 2025 and 37.4% earnings growth year-over-year. Despi…
Accumulation Zones
| Metric |
ABBV |
DDOG |
| Zone Low |
$163.13 |
$122.26 |
| Zone High |
$184.88 |
$138.56 |
| In Buy Zone? |
No
|
Yes
|